Midostaurin resistance was overcome by a combination of midostaruin, the BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant acute myeloid leukemia (AML) cell lines and primary samples, providing the first evidence of a potential new treatment approach to eradicate FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication + AML.
[Communications Biology]
7992332
M985GR7A
items
1
apa
0
default
asc
1
163966
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
